STK11 and lung carcinoma: According to current studies related to lung cancer patients with KRAS mutations, the most common co-mutated gene is tumor protein p53 gene (TP53), which accounts for about 39–42% of patients with KRAS mutations, followed by serine/threonine kinase 11 gene (STK11), accounting for about 20–30%, and kelch-like ECH associated protein 1 gene (KEAP1), accounting for about 13–27% [46,47].